Overexpression of others genes included in our signature, MSI2 (Musashi 2) and SOCS2 (Suppressor of cytokines signaling 2), predicted unfavorable outcome in AML and chronic myeloid leukemia (CML) [17,18]. Here, SOCS2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.